← Back to Search

Aromatase Inhibitor

Letrozole for Hepatopulmonary Syndrome

Phase 2
Recruiting
Led By Hilary M DuBrock, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 and 6 months
Awards & highlights

Study Summary

This trial is testing if letrozole is safe and helpful for people with Hepatopulmonary Syndrome.

Eligible Conditions
  • Hepatopulmonary Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Alveolar-Arterial Oxygen
Secondary outcome measures
Hormone Levels
Oxygen Saturation
Side effects

Side effects data

From 2018 Phase 4 trial • 79 Patients • NCT02137538
10%
Fracture
8%
Acne
5%
Scoliosis
3%
Hair loss
3%
Sacroiliitis
3%
Neuro event
100%
80%
60%
40%
20%
0%
Study treatment Arm
Anastrozole
Letrozole

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Letrozole GroupExperimental Treatment1 Intervention
Subjects with hepatopulmonary syndrome will get the study drug letrozole
Group II: Placebo GroupPlacebo Group1 Intervention
Subjects with hepatopulmonary syndrome will get the study placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Letrozole
2002
Completed Phase 4
~3240

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor
3,205 Previous Clinical Trials
3,766,764 Total Patients Enrolled
1 Trials studying Hepatopulmonary Syndrome
10 Patients Enrolled for Hepatopulmonary Syndrome
University of California, San FranciscoOTHER
2,500 Previous Clinical Trials
15,236,451 Total Patients Enrolled
Hilary M DuBrock, MDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
390 Total Patients Enrolled

Media Library

Letrozole (Aromatase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04577001 — Phase 2
Hepatopulmonary Syndrome Research Study Groups: Letrozole Group, Placebo Group
Hepatopulmonary Syndrome Clinical Trial 2023: Letrozole Highlights & Side Effects. Trial Name: NCT04577001 — Phase 2
Letrozole (Aromatase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04577001 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To whom is this research opportunity applicable?

"This clinical experiment seeks to recruit 20 individuals with hepatopulmonary syndrome. Age criteria are between 18 and 99; however, other qualifications must also be met by participants. These include the presence of liver disease or portal hypertension, a contrast-enhanced echocardiogram showing intrapulmonary shunting, an A-a gradient ≥15mmHg (or ≥20mmHg if above 64 years old) and PaO2<80mmHg on arterial blood gas testing, Child-Pugh class A or B liver disease, MELD score < 20 for females who have experienced 12 months of natural amen"

Answered by AI

Is this trial accepting new applicants at the present time?

"Affirmative. Clinicaltrials.gov indicates that this trial has been open since January 25th 2021 and is actively searching for 20 volunteers across 2 sites. The most recent update was made on March 23rd 2022."

Answered by AI

Is there an age limitation to participating in this experiment?

"This medical trail is recruiting adults aged 18 to 99."

Answered by AI

Has Letrozole been sanctioned by the FDA?

"Our safety assessment of letrozole was a 2, as it is only in Phase 2 trials and therefore lacks verifiable evidence for effectiveness."

Answered by AI

How many participants are currently enrolled in this research program?

"Affirmative. Clinicaltrials.gov data reveals that this medical trial is still actively seeking patients, having initially been posted on January 25th 2021 and last updated on March 23rd 2022. The study requires 20 individuals to be recruited from 2 separate sites."

Answered by AI

What evidence do we have that Letrozole may be beneficial for medical uses?

"Letrozole has been an area of research since 1995, with 18503 trials completed and 154 presently active. A substantial proportion of these investigations are being conducted in San Francisco, California."

Answered by AI

What maladies does Letrozole typically address?

"Letrozole can be utilized to manage breast cancer, anovulatory cycle issues, and tamoxifen related treatments."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Letrozole in Patients With Hepatopulmonary Syndrome
Hilary M. DuBrock, MD 2021. "Letrozole in Patients With Hepatopulmonary Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04577001.
~5 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top